Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.
Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for surgical prophylaxis in patients with Glanzmann thrombasthenia as reported to the International Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the Registry data is the heterogeneity of treatment protocol, including dosage, number of doses used, duration of treatment before declaration of failure, and mode of rFVIIa administration (bolus v continuous infusion). The data are not yet sufficient to define optimal regimens for various indications such as the type of bleeding or the type of procedures. The place of this drug compared to platelet transfusion in the overall management of patients with Glanzmann thrombasthenia will need to be determined in relationship to a number of challenges and unresolved issues in the clinical care of these patients. These issues include: how to improve local measures for patients with mucosal bleeds, optimal management of young women during menarche, optimal platelet transfusion regimens for various indications, the relationship between antiplatelet antibodies detected by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and effectiveness of platelet transfusion, whether there are other biological tests that may correlate with effectiveness of platelet transfusion, and management of pregnancy and delivery regarding antiplatelet immunization.
Poon
M C
MC
Hemophilia/Hemostasis Centres in Canada. mcpoon@ucalgary.ca
d'Oiron
R
R
Hann
I
I
Négrier
C
C
de Lumley
L
L
Thomas
A
A
Karafoulidou
A
A
Demers
C
C
Street
A
A
Huth-Kühne
A
A
Petrini
P
P
Fressinaud
E
E
Morfini
M
M
Tengborn
L
L
Marquès-Verdier
A
A
Musso
R
R
Devecioglu
O
O
Houston
D S
DS
Lethagen
S
S
Van Geet
C
C
von Depka
M
M
Berger
C
C
Beurrier
P
P
Britton
H A
HA
Gerrits
W
W
Guthner
C
C
Kuhle
S
S
Lorenzo
J J
JJ
Makris
P E
PE
Nohe
N
N
Paugy
P
P
Pautard
B
B
Torchet
M F
MF
Trillot
N
N
Vicariot
M
M
Wilde
J
J
Winter
M
M
Chambost
H
H
Ingerslev
J
J
Peters
M
M
Strauss
G
G
D003029:Coagulants / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D008297:Male; D017713:Platelet Transfusion / Q000009:adverse effects; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013915:Thrombasthenia / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy
D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa